nodes	percent_of_prediction	percent_of_DWPC	metapath
Mefloquine—ABCB1—Mitoxantrone—lymphatic system cancer	0.0705	0.207	CbGbCtD
Mefloquine—CYP3A4—Cytarabine—lymphatic system cancer	0.0613	0.18	CbGbCtD
Mefloquine—CYP3A4—Teniposide—lymphatic system cancer	0.0604	0.177	CbGbCtD
Mefloquine—ABCB1—Vincristine—lymphatic system cancer	0.0485	0.142	CbGbCtD
Mefloquine—CYP3A4—Mitoxantrone—lymphatic system cancer	0.0422	0.124	CbGbCtD
Mefloquine—ABCB1—Methotrexate—lymphatic system cancer	0.0294	0.086	CbGbCtD
Mefloquine—CYP3A4—Vincristine—lymphatic system cancer	0.0291	0.0851	CbGbCtD
Mefloquine—Alopecia—Bleomycin—lymphatic system cancer	0.00186	0.00282	CcSEcCtD
Mefloquine—Musculoskeletal discomfort—Fludarabine—lymphatic system cancer	0.00186	0.00282	CcSEcCtD
Mefloquine—Urticaria—Teniposide—lymphatic system cancer	0.00184	0.0028	CcSEcCtD
Mefloquine—Abdominal pain—Teniposide—lymphatic system cancer	0.00183	0.00278	CcSEcCtD
Mefloquine—Body temperature increased—Teniposide—lymphatic system cancer	0.00183	0.00278	CcSEcCtD
Mefloquine—Erythema—Bleomycin—lymphatic system cancer	0.00183	0.00278	CcSEcCtD
Mefloquine—Paraesthesia—Fludarabine—lymphatic system cancer	0.00183	0.00278	CcSEcCtD
Mefloquine—Hallucination—Carmustine—lymphatic system cancer	0.00183	0.00277	CcSEcCtD
Mefloquine—Sweating—Mitoxantrone—lymphatic system cancer	0.00182	0.00277	CcSEcCtD
Mefloquine—Dyspnoea—Fludarabine—lymphatic system cancer	0.00182	0.00276	CcSEcCtD
Mefloquine—Connective tissue disorder—Carmustine—lymphatic system cancer	0.0018	0.00274	CcSEcCtD
Mefloquine—Dyspepsia—Fludarabine—lymphatic system cancer	0.00179	0.00272	CcSEcCtD
Mefloquine—Agranulocytosis—Mitoxantrone—lymphatic system cancer	0.00177	0.00269	CcSEcCtD
Mefloquine—Decreased appetite—Fludarabine—lymphatic system cancer	0.00177	0.00269	CcSEcCtD
Mefloquine—Visual impairment—Carmustine—lymphatic system cancer	0.00177	0.00269	CcSEcCtD
Mefloquine—Gastrointestinal disorder—Fludarabine—lymphatic system cancer	0.00176	0.00267	CcSEcCtD
Mefloquine—Fatigue—Fludarabine—lymphatic system cancer	0.00176	0.00267	CcSEcCtD
Mefloquine—Hallucination—Vincristine—lymphatic system cancer	0.00174	0.00265	CcSEcCtD
Mefloquine—Bradycardia—Mitoxantrone—lymphatic system cancer	0.00174	0.00264	CcSEcCtD
Mefloquine—Connective tissue disorder—Vincristine—lymphatic system cancer	0.00172	0.00261	CcSEcCtD
Mefloquine—Eye disorder—Carmustine—lymphatic system cancer	0.00172	0.00261	CcSEcCtD
Mefloquine—Hypersensitivity—Teniposide—lymphatic system cancer	0.00171	0.00259	CcSEcCtD
Mefloquine—Flushing—Carmustine—lymphatic system cancer	0.0017	0.00259	CcSEcCtD
Mefloquine—Ill-defined disorder—Bleomycin—lymphatic system cancer	0.0017	0.00258	CcSEcCtD
Mefloquine—Feeling abnormal—Fludarabine—lymphatic system cancer	0.00168	0.00255	CcSEcCtD
Mefloquine—Asthenia—Teniposide—lymphatic system cancer	0.00166	0.00253	CcSEcCtD
Mefloquine—Malaise—Bleomycin—lymphatic system cancer	0.00165	0.00251	CcSEcCtD
Mefloquine—Pruritus—Teniposide—lymphatic system cancer	0.00164	0.00249	CcSEcCtD
Mefloquine—Leukopenia—Bleomycin—lymphatic system cancer	0.00164	0.00249	CcSEcCtD
Mefloquine—Cardiac disorder—Vincristine—lymphatic system cancer	0.00163	0.00247	CcSEcCtD
Mefloquine—Alopecia—Carmustine—lymphatic system cancer	0.00162	0.00246	CcSEcCtD
Mefloquine—Body temperature increased—Fludarabine—lymphatic system cancer	0.00161	0.00245	CcSEcCtD
Mefloquine—Mental disorder—Carmustine—lymphatic system cancer	0.00161	0.00244	CcSEcCtD
Mefloquine—Malnutrition—Carmustine—lymphatic system cancer	0.0016	0.00243	CcSEcCtD
Mefloquine—Erythema—Carmustine—lymphatic system cancer	0.0016	0.00243	CcSEcCtD
Mefloquine—Angiopathy—Vincristine—lymphatic system cancer	0.00159	0.00241	CcSEcCtD
Mefloquine—Aplastic anaemia—Methotrexate—lymphatic system cancer	0.00159	0.00241	CcSEcCtD
Mefloquine—Diarrhoea—Teniposide—lymphatic system cancer	0.00159	0.00241	CcSEcCtD
Mefloquine—Mediastinal disorder—Vincristine—lymphatic system cancer	0.00158	0.0024	CcSEcCtD
Mefloquine—Myalgia—Bleomycin—lymphatic system cancer	0.00156	0.00237	CcSEcCtD
Mefloquine—Chest pain—Bleomycin—lymphatic system cancer	0.00156	0.00237	CcSEcCtD
Mefloquine—Alopecia—Vincristine—lymphatic system cancer	0.00155	0.00235	CcSEcCtD
Mefloquine—Coma—Methotrexate—lymphatic system cancer	0.00155	0.00235	CcSEcCtD
Mefloquine—Discomfort—Bleomycin—lymphatic system cancer	0.00154	0.00234	CcSEcCtD
Mefloquine—Mental disorder—Vincristine—lymphatic system cancer	0.00154	0.00233	CcSEcCtD
Mefloquine—Chills—Mitoxantrone—lymphatic system cancer	0.00153	0.00233	CcSEcCtD
Mefloquine—Alopecia—Mitoxantrone—lymphatic system cancer	0.00151	0.00229	CcSEcCtD
Mefloquine—Confusional state—Bleomycin—lymphatic system cancer	0.00151	0.00229	CcSEcCtD
Mefloquine—Vision blurred—Carmustine—lymphatic system cancer	0.00151	0.00229	CcSEcCtD
Mefloquine—Hypersensitivity—Fludarabine—lymphatic system cancer	0.0015	0.00228	CcSEcCtD
Mefloquine—Tremor—Carmustine—lymphatic system cancer	0.0015	0.00227	CcSEcCtD
Mefloquine—Oedema—Bleomycin—lymphatic system cancer	0.00149	0.00227	CcSEcCtD
Mefloquine—Anaphylactic shock—Bleomycin—lymphatic system cancer	0.00149	0.00227	CcSEcCtD
Mefloquine—Erythema—Mitoxantrone—lymphatic system cancer	0.00149	0.00226	CcSEcCtD
Mefloquine—Vomiting—Teniposide—lymphatic system cancer	0.00147	0.00224	CcSEcCtD
Mefloquine—Agitation—Carmustine—lymphatic system cancer	0.00147	0.00223	CcSEcCtD
Mefloquine—Thrombocytopenia—Bleomycin—lymphatic system cancer	0.00146	0.00222	CcSEcCtD
Mefloquine—Asthenia—Fludarabine—lymphatic system cancer	0.00146	0.00222	CcSEcCtD
Mefloquine—Rash—Teniposide—lymphatic system cancer	0.00146	0.00222	CcSEcCtD
Mefloquine—Dermatitis—Teniposide—lymphatic system cancer	0.00146	0.00222	CcSEcCtD
Mefloquine—Headache—Teniposide—lymphatic system cancer	0.00145	0.00221	CcSEcCtD
Mefloquine—Pruritus—Fludarabine—lymphatic system cancer	0.00144	0.00219	CcSEcCtD
Mefloquine—Leukopenia—Carmustine—lymphatic system cancer	0.00143	0.00217	CcSEcCtD
Mefloquine—Agitation—Vincristine—lymphatic system cancer	0.0014	0.00213	CcSEcCtD
Mefloquine—Vision blurred—Mitoxantrone—lymphatic system cancer	0.0014	0.00213	CcSEcCtD
Mefloquine—Hypotension—Bleomycin—lymphatic system cancer	0.0014	0.00212	CcSEcCtD
Mefloquine—Diarrhoea—Fludarabine—lymphatic system cancer	0.00139	0.00212	CcSEcCtD
Mefloquine—Convulsion—Carmustine—lymphatic system cancer	0.00138	0.0021	CcSEcCtD
Mefloquine—Hypertension—Carmustine—lymphatic system cancer	0.00138	0.0021	CcSEcCtD
Mefloquine—Ill-defined disorder—Mitoxantrone—lymphatic system cancer	0.00138	0.00209	CcSEcCtD
Mefloquine—Nausea—Teniposide—lymphatic system cancer	0.00138	0.00209	CcSEcCtD
Mefloquine—Vertigo—Vincristine—lymphatic system cancer	0.00137	0.00208	CcSEcCtD
Mefloquine—Hepatic failure—Methotrexate—lymphatic system cancer	0.00137	0.00208	CcSEcCtD
Mefloquine—Leukopenia—Vincristine—lymphatic system cancer	0.00137	0.00207	CcSEcCtD
Mefloquine—Musculoskeletal discomfort—Bleomycin—lymphatic system cancer	0.00136	0.00207	CcSEcCtD
Mefloquine—Chest pain—Carmustine—lymphatic system cancer	0.00136	0.00207	CcSEcCtD
Mefloquine—Myalgia—Carmustine—lymphatic system cancer	0.00136	0.00207	CcSEcCtD
Mefloquine—Anxiety—Carmustine—lymphatic system cancer	0.00136	0.00206	CcSEcCtD
Mefloquine—Paraesthesia—Bleomycin—lymphatic system cancer	0.00134	0.00204	CcSEcCtD
Mefloquine—Malaise—Mitoxantrone—lymphatic system cancer	0.00134	0.00203	CcSEcCtD
Mefloquine—Dyspnoea—Bleomycin—lymphatic system cancer	0.00133	0.00202	CcSEcCtD
Mefloquine—Leukopenia—Mitoxantrone—lymphatic system cancer	0.00133	0.00202	CcSEcCtD
Mefloquine—Convulsion—Vincristine—lymphatic system cancer	0.00132	0.00201	CcSEcCtD
Mefloquine—Hypertension—Vincristine—lymphatic system cancer	0.00132	0.002	CcSEcCtD
Mefloquine—Confusional state—Carmustine—lymphatic system cancer	0.00132	0.002	CcSEcCtD
Mefloquine—Oedema—Carmustine—lymphatic system cancer	0.0013	0.00198	CcSEcCtD
Mefloquine—Decreased appetite—Bleomycin—lymphatic system cancer	0.0013	0.00197	CcSEcCtD
Mefloquine—Myalgia—Vincristine—lymphatic system cancer	0.0013	0.00197	CcSEcCtD
Mefloquine—Visual disturbance—Methotrexate—lymphatic system cancer	0.0013	0.00197	CcSEcCtD
Mefloquine—Vomiting—Fludarabine—lymphatic system cancer	0.0013	0.00197	CcSEcCtD
Mefloquine—Convulsion—Mitoxantrone—lymphatic system cancer	0.00129	0.00195	CcSEcCtD
Mefloquine—Rash—Fludarabine—lymphatic system cancer	0.00129	0.00195	CcSEcCtD
Mefloquine—Dermatitis—Fludarabine—lymphatic system cancer	0.00128	0.00195	CcSEcCtD
Mefloquine—Hypertension—Mitoxantrone—lymphatic system cancer	0.00128	0.00195	CcSEcCtD
Mefloquine—Thrombocytopenia—Carmustine—lymphatic system cancer	0.00128	0.00194	CcSEcCtD
Mefloquine—Headache—Fludarabine—lymphatic system cancer	0.00128	0.00194	CcSEcCtD
Mefloquine—Tachycardia—Carmustine—lymphatic system cancer	0.00127	0.00193	CcSEcCtD
Mefloquine—Arthralgia—Mitoxantrone—lymphatic system cancer	0.00127	0.00192	CcSEcCtD
Mefloquine—Chest pain—Mitoxantrone—lymphatic system cancer	0.00127	0.00192	CcSEcCtD
Mefloquine—Myalgia—Mitoxantrone—lymphatic system cancer	0.00127	0.00192	CcSEcCtD
Mefloquine—Anxiety—Mitoxantrone—lymphatic system cancer	0.00126	0.00191	CcSEcCtD
Mefloquine—Discomfort—Mitoxantrone—lymphatic system cancer	0.00125	0.0019	CcSEcCtD
Mefloquine—Oedema—Vincristine—lymphatic system cancer	0.00125	0.00189	CcSEcCtD
Mefloquine—Anaphylactic shock—Vincristine—lymphatic system cancer	0.00125	0.00189	CcSEcCtD
Mefloquine—Feeling abnormal—Bleomycin—lymphatic system cancer	0.00123	0.00187	CcSEcCtD
Mefloquine—Confusional state—Mitoxantrone—lymphatic system cancer	0.00122	0.00186	CcSEcCtD
Mefloquine—Nervous system disorder—Vincristine—lymphatic system cancer	0.00122	0.00185	CcSEcCtD
Mefloquine—Thrombocytopenia—Vincristine—lymphatic system cancer	0.00122	0.00185	CcSEcCtD
Mefloquine—Hypotension—Carmustine—lymphatic system cancer	0.00122	0.00185	CcSEcCtD
Mefloquine—Anaphylactic shock—Mitoxantrone—lymphatic system cancer	0.00121	0.00184	CcSEcCtD
Mefloquine—Oedema—Mitoxantrone—lymphatic system cancer	0.00121	0.00184	CcSEcCtD
Mefloquine—Nausea—Fludarabine—lymphatic system cancer	0.00121	0.00184	CcSEcCtD
Mefloquine—Hyperhidrosis—Vincristine—lymphatic system cancer	0.0012	0.00183	CcSEcCtD
Mefloquine—Shock—Mitoxantrone—lymphatic system cancer	0.00119	0.00181	CcSEcCtD
Mefloquine—Musculoskeletal discomfort—Carmustine—lymphatic system cancer	0.00119	0.0018	CcSEcCtD
Mefloquine—Thrombocytopenia—Mitoxantrone—lymphatic system cancer	0.00119	0.0018	CcSEcCtD
Mefloquine—Urticaria—Bleomycin—lymphatic system cancer	0.00119	0.0018	CcSEcCtD
Mefloquine—Tachycardia—Mitoxantrone—lymphatic system cancer	0.00118	0.0018	CcSEcCtD
Mefloquine—Body temperature increased—Bleomycin—lymphatic system cancer	0.00118	0.00179	CcSEcCtD
Mefloquine—Insomnia—Carmustine—lymphatic system cancer	0.00118	0.00179	CcSEcCtD
Mefloquine—Skin disorder—Mitoxantrone—lymphatic system cancer	0.00118	0.00179	CcSEcCtD
Mefloquine—Irritability—Methotrexate—lymphatic system cancer	0.00117	0.00178	CcSEcCtD
Mefloquine—Hyperhidrosis—Mitoxantrone—lymphatic system cancer	0.00117	0.00178	CcSEcCtD
Mefloquine—Paraesthesia—Carmustine—lymphatic system cancer	0.00117	0.00178	CcSEcCtD
Mefloquine—Mood swings—Methotrexate—lymphatic system cancer	0.00116	0.00177	CcSEcCtD
Mefloquine—Hypotension—Vincristine—lymphatic system cancer	0.00116	0.00177	CcSEcCtD
Mefloquine—Dyspnoea—Carmustine—lymphatic system cancer	0.00116	0.00177	CcSEcCtD
Mefloquine—Somnolence—Carmustine—lymphatic system cancer	0.00116	0.00176	CcSEcCtD
Mefloquine—Ataxia—Methotrexate—lymphatic system cancer	0.00116	0.00175	CcSEcCtD
Mefloquine—Musculoskeletal discomfort—Vincristine—lymphatic system cancer	0.00113	0.00172	CcSEcCtD
Mefloquine—Decreased appetite—Carmustine—lymphatic system cancer	0.00113	0.00172	CcSEcCtD
Mefloquine—Hypotension—Mitoxantrone—lymphatic system cancer	0.00113	0.00172	CcSEcCtD
Mefloquine—Insomnia—Vincristine—lymphatic system cancer	0.00113	0.00171	CcSEcCtD
Mefloquine—Gastrointestinal disorder—Carmustine—lymphatic system cancer	0.00113	0.00171	CcSEcCtD
Mefloquine—Paraesthesia—Vincristine—lymphatic system cancer	0.00112	0.0017	CcSEcCtD
Mefloquine—Musculoskeletal discomfort—Mitoxantrone—lymphatic system cancer	0.0011	0.00168	CcSEcCtD
Mefloquine—Hypersensitivity—Bleomycin—lymphatic system cancer	0.0011	0.00167	CcSEcCtD
Mefloquine—Paraesthesia—Mitoxantrone—lymphatic system cancer	0.00109	0.00165	CcSEcCtD
Mefloquine—Decreased appetite—Vincristine—lymphatic system cancer	0.00108	0.00164	CcSEcCtD
Mefloquine—Dyspnoea—Mitoxantrone—lymphatic system cancer	0.00108	0.00164	CcSEcCtD
Mefloquine—Somnolence—Mitoxantrone—lymphatic system cancer	0.00108	0.00164	CcSEcCtD
Mefloquine—Gastrointestinal disorder—Vincristine—lymphatic system cancer	0.00108	0.00163	CcSEcCtD
Mefloquine—Feeling abnormal—Carmustine—lymphatic system cancer	0.00107	0.00163	CcSEcCtD
Mefloquine—Fatigue—Vincristine—lymphatic system cancer	0.00107	0.00163	CcSEcCtD
Mefloquine—Asthenia—Bleomycin—lymphatic system cancer	0.00107	0.00163	CcSEcCtD
Mefloquine—Dyspepsia—Mitoxantrone—lymphatic system cancer	0.00107	0.00162	CcSEcCtD
Mefloquine—Gastrointestinal pain—Carmustine—lymphatic system cancer	0.00107	0.00162	CcSEcCtD
Mefloquine—Pruritus—Bleomycin—lymphatic system cancer	0.00106	0.00161	CcSEcCtD
Mefloquine—Decreased appetite—Mitoxantrone—lymphatic system cancer	0.00105	0.0016	CcSEcCtD
Mefloquine—Fatigue—Mitoxantrone—lymphatic system cancer	0.00105	0.00159	CcSEcCtD
Mefloquine—Abdominal pain—Carmustine—lymphatic system cancer	0.00103	0.00157	CcSEcCtD
Mefloquine—Body temperature increased—Carmustine—lymphatic system cancer	0.00103	0.00157	CcSEcCtD
Mefloquine—Gastrointestinal pain—Vincristine—lymphatic system cancer	0.00102	0.00155	CcSEcCtD
Mefloquine—Feeling abnormal—Mitoxantrone—lymphatic system cancer	0.000999	0.00152	CcSEcCtD
Mefloquine—Gastrointestinal pain—Mitoxantrone—lymphatic system cancer	0.000992	0.00151	CcSEcCtD
Mefloquine—Abdominal pain—Vincristine—lymphatic system cancer	0.000984	0.00149	CcSEcCtD
Mefloquine—Body temperature increased—Vincristine—lymphatic system cancer	0.000984	0.00149	CcSEcCtD
Mefloquine—Urticaria—Mitoxantrone—lymphatic system cancer	0.000963	0.00146	CcSEcCtD
Mefloquine—Hypersensitivity—Carmustine—lymphatic system cancer	0.000961	0.00146	CcSEcCtD
Mefloquine—Abdominal pain—Mitoxantrone—lymphatic system cancer	0.000959	0.00146	CcSEcCtD
Mefloquine—Body temperature increased—Mitoxantrone—lymphatic system cancer	0.000959	0.00146	CcSEcCtD
Mefloquine—Pneumonia—Methotrexate—lymphatic system cancer	0.000953	0.00145	CcSEcCtD
Mefloquine—Vomiting—Bleomycin—lymphatic system cancer	0.00095	0.00144	CcSEcCtD
Mefloquine—Rash—Bleomycin—lymphatic system cancer	0.000942	0.00143	CcSEcCtD
Mefloquine—Dermatitis—Bleomycin—lymphatic system cancer	0.000941	0.00143	CcSEcCtD
Mefloquine—Stevens-Johnson syndrome—Methotrexate—lymphatic system cancer	0.000939	0.00143	CcSEcCtD
Mefloquine—Asthenia—Carmustine—lymphatic system cancer	0.000936	0.00142	CcSEcCtD
Mefloquine—Renal failure—Methotrexate—lymphatic system cancer	0.000931	0.00141	CcSEcCtD
Mefloquine—Hypersensitivity—Vincristine—lymphatic system cancer	0.000917	0.00139	CcSEcCtD
Mefloquine—Sweating—Methotrexate—lymphatic system cancer	0.000908	0.00138	CcSEcCtD
Mefloquine—Hepatobiliary disease—Methotrexate—lymphatic system cancer	0.000896	0.00136	CcSEcCtD
Mefloquine—Hypersensitivity—Mitoxantrone—lymphatic system cancer	0.000893	0.00136	CcSEcCtD
Mefloquine—Asthenia—Vincristine—lymphatic system cancer	0.000893	0.00136	CcSEcCtD
Mefloquine—Diarrhoea—Carmustine—lymphatic system cancer	0.000893	0.00136	CcSEcCtD
Mefloquine—Nausea—Bleomycin—lymphatic system cancer	0.000888	0.00135	CcSEcCtD
Mefloquine—Agranulocytosis—Methotrexate—lymphatic system cancer	0.000884	0.00134	CcSEcCtD
Mefloquine—Asthenia—Mitoxantrone—lymphatic system cancer	0.00087	0.00132	CcSEcCtD
Mefloquine—Dizziness—Carmustine—lymphatic system cancer	0.000863	0.00131	CcSEcCtD
Mefloquine—Diarrhoea—Vincristine—lymphatic system cancer	0.000852	0.00129	CcSEcCtD
Mefloquine—Diarrhoea—Mitoxantrone—lymphatic system cancer	0.00083	0.00126	CcSEcCtD
Mefloquine—Vomiting—Carmustine—lymphatic system cancer	0.000829	0.00126	CcSEcCtD
Mefloquine—Dizziness—Vincristine—lymphatic system cancer	0.000823	0.00125	CcSEcCtD
Mefloquine—Rash—Carmustine—lymphatic system cancer	0.000822	0.00125	CcSEcCtD
Mefloquine—Dermatitis—Carmustine—lymphatic system cancer	0.000822	0.00125	CcSEcCtD
Mefloquine—Visual impairment—Methotrexate—lymphatic system cancer	0.00082	0.00124	CcSEcCtD
Mefloquine—Headache—Carmustine—lymphatic system cancer	0.000817	0.00124	CcSEcCtD
Mefloquine—Erythema multiforme—Methotrexate—lymphatic system cancer	0.000804	0.00122	CcSEcCtD
Mefloquine—Eye disorder—Methotrexate—lymphatic system cancer	0.000795	0.00121	CcSEcCtD
Mefloquine—Tinnitus—Methotrexate—lymphatic system cancer	0.000793	0.0012	CcSEcCtD
Mefloquine—Vomiting—Vincristine—lymphatic system cancer	0.000792	0.0012	CcSEcCtD
Mefloquine—Cardiac disorder—Methotrexate—lymphatic system cancer	0.000789	0.0012	CcSEcCtD
Mefloquine—Rash—Vincristine—lymphatic system cancer	0.000785	0.00119	CcSEcCtD
Mefloquine—Dermatitis—Vincristine—lymphatic system cancer	0.000784	0.00119	CcSEcCtD
Mefloquine—Headache—Vincristine—lymphatic system cancer	0.00078	0.00118	CcSEcCtD
Mefloquine—Nausea—Carmustine—lymphatic system cancer	0.000775	0.00118	CcSEcCtD
Mefloquine—Angiopathy—Methotrexate—lymphatic system cancer	0.000772	0.00117	CcSEcCtD
Mefloquine—Vomiting—Mitoxantrone—lymphatic system cancer	0.000771	0.00117	CcSEcCtD
Mefloquine—Mediastinal disorder—Methotrexate—lymphatic system cancer	0.000766	0.00116	CcSEcCtD
Mefloquine—Rash—Mitoxantrone—lymphatic system cancer	0.000765	0.00116	CcSEcCtD
Mefloquine—Dermatitis—Mitoxantrone—lymphatic system cancer	0.000764	0.00116	CcSEcCtD
Mefloquine—Chills—Methotrexate—lymphatic system cancer	0.000763	0.00116	CcSEcCtD
Mefloquine—Headache—Mitoxantrone—lymphatic system cancer	0.00076	0.00115	CcSEcCtD
Mefloquine—Alopecia—Methotrexate—lymphatic system cancer	0.000752	0.00114	CcSEcCtD
Mefloquine—Mental disorder—Methotrexate—lymphatic system cancer	0.000745	0.00113	CcSEcCtD
Mefloquine—Erythema—Methotrexate—lymphatic system cancer	0.00074	0.00112	CcSEcCtD
Mefloquine—Malnutrition—Methotrexate—lymphatic system cancer	0.00074	0.00112	CcSEcCtD
Mefloquine—Nausea—Vincristine—lymphatic system cancer	0.00074	0.00112	CcSEcCtD
Mefloquine—Nausea—Mitoxantrone—lymphatic system cancer	0.00072	0.00109	CcSEcCtD
Mefloquine—Vision blurred—Methotrexate—lymphatic system cancer	0.000698	0.00106	CcSEcCtD
Mefloquine—Ill-defined disorder—Methotrexate—lymphatic system cancer	0.000687	0.00104	CcSEcCtD
Mefloquine—Malaise—Methotrexate—lymphatic system cancer	0.000668	0.00101	CcSEcCtD
Mefloquine—Vertigo—Methotrexate—lymphatic system cancer	0.000665	0.00101	CcSEcCtD
Mefloquine—Leukopenia—Methotrexate—lymphatic system cancer	0.000663	0.00101	CcSEcCtD
Mefloquine—Convulsion—Methotrexate—lymphatic system cancer	0.000641	0.000974	CcSEcCtD
Mefloquine—Myalgia—Methotrexate—lymphatic system cancer	0.00063	0.000957	CcSEcCtD
Mefloquine—Arthralgia—Methotrexate—lymphatic system cancer	0.00063	0.000957	CcSEcCtD
Mefloquine—Chest pain—Methotrexate—lymphatic system cancer	0.00063	0.000957	CcSEcCtD
Mefloquine—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—lymphatic system cancer	0.000626	0.00095	CcSEcCtD
Mefloquine—Discomfort—Methotrexate—lymphatic system cancer	0.000623	0.000945	CcSEcCtD
Mefloquine—Confusional state—Methotrexate—lymphatic system cancer	0.000609	0.000925	CcSEcCtD
Mefloquine—Anaphylactic shock—Methotrexate—lymphatic system cancer	0.000604	0.000917	CcSEcCtD
Mefloquine—Nervous system disorder—Methotrexate—lymphatic system cancer	0.000593	0.0009	CcSEcCtD
Mefloquine—Thrombocytopenia—Methotrexate—lymphatic system cancer	0.000592	0.000898	CcSEcCtD
Mefloquine—Skin disorder—Methotrexate—lymphatic system cancer	0.000587	0.000891	CcSEcCtD
Mefloquine—Hyperhidrosis—Methotrexate—lymphatic system cancer	0.000584	0.000887	CcSEcCtD
Mefloquine—Hypotension—Methotrexate—lymphatic system cancer	0.000565	0.000857	CcSEcCtD
Mefloquine—Musculoskeletal discomfort—Methotrexate—lymphatic system cancer	0.00055	0.000836	CcSEcCtD
Mefloquine—Insomnia—Methotrexate—lymphatic system cancer	0.000546	0.00083	CcSEcCtD
Mefloquine—Paraesthesia—Methotrexate—lymphatic system cancer	0.000543	0.000824	CcSEcCtD
Mefloquine—Dyspnoea—Methotrexate—lymphatic system cancer	0.000539	0.000818	CcSEcCtD
Mefloquine—Somnolence—Methotrexate—lymphatic system cancer	0.000537	0.000815	CcSEcCtD
Mefloquine—Dyspepsia—Methotrexate—lymphatic system cancer	0.000532	0.000807	CcSEcCtD
Mefloquine—Decreased appetite—Methotrexate—lymphatic system cancer	0.000525	0.000797	CcSEcCtD
Mefloquine—Gastrointestinal disorder—Methotrexate—lymphatic system cancer	0.000522	0.000792	CcSEcCtD
Mefloquine—Fatigue—Methotrexate—lymphatic system cancer	0.000521	0.000791	CcSEcCtD
Mefloquine—Feeling abnormal—Methotrexate—lymphatic system cancer	0.000498	0.000756	CcSEcCtD
Mefloquine—Gastrointestinal pain—Methotrexate—lymphatic system cancer	0.000494	0.00075	CcSEcCtD
Mefloquine—Urticaria—Methotrexate—lymphatic system cancer	0.00048	0.000729	CcSEcCtD
Mefloquine—Abdominal pain—Methotrexate—lymphatic system cancer	0.000478	0.000725	CcSEcCtD
Mefloquine—Body temperature increased—Methotrexate—lymphatic system cancer	0.000478	0.000725	CcSEcCtD
Mefloquine—Hypersensitivity—Methotrexate—lymphatic system cancer	0.000445	0.000676	CcSEcCtD
Mefloquine—Asthenia—Methotrexate—lymphatic system cancer	0.000434	0.000658	CcSEcCtD
Mefloquine—Pruritus—Methotrexate—lymphatic system cancer	0.000427	0.000649	CcSEcCtD
Mefloquine—Diarrhoea—Methotrexate—lymphatic system cancer	0.000413	0.000628	CcSEcCtD
Mefloquine—Dizziness—Methotrexate—lymphatic system cancer	0.0004	0.000607	CcSEcCtD
Mefloquine—Vomiting—Methotrexate—lymphatic system cancer	0.000384	0.000583	CcSEcCtD
Mefloquine—Rash—Methotrexate—lymphatic system cancer	0.000381	0.000578	CcSEcCtD
Mefloquine—Dermatitis—Methotrexate—lymphatic system cancer	0.000381	0.000578	CcSEcCtD
Mefloquine—Headache—Methotrexate—lymphatic system cancer	0.000379	0.000575	CcSEcCtD
Mefloquine—Nausea—Methotrexate—lymphatic system cancer	0.000359	0.000545	CcSEcCtD
